- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01459744
An Intervention to Improve Implantable Cardioverter-Defibrillator Deactivation Conversations (WISDOM)
An Intervention to Improve ICD Deactivation Conversations (WISDOM - Working to Improve discuSsions About DefibrillatOr Management)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80045
- University of Colorado - Denver
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06510
- Yale New-Haven Hospital
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Mayo Medical Center
-
-
New York
-
Bronx, New York, Stati Uniti, 10023
- Montefiore Medical Center
-
New York, New York, Stati Uniti, 10029
- Icahn School Of Medicine At Mount Sinai
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Hospital of the University of Pennsylvania
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Clinicians:
- At all sites, a core group of approximately 10 heart failure clinicians (physicians, nurses) care exclusively for patients with advanced heart failure in both inpatient and outpatient settings; all of these clinicians are eligible..
Patients:
- Patient does not currently have a ventricular assist device
- Age > 18
- Fluent in English
- Consistent and reliable access to a phone
For Inpatient:
- Has had at least 1 other heart failure in the last year, OR
Meets all three of the following criteria at time of admission:
- BUN > 43
- SBP ≤ 115
- CR > 2.75 OR
- Was on inotropes OR intravenous diuretics OR intravenous heart failure treatments in emergency department OR in outpatient setting prior to the current hospital admission
For Outpatient
- Has had 2 or more heart failure related admissions in the last year OR
- Has class IV heart failure in the outpatient setting OR
- Has Class III heart failure in outpatient setting AND 1 heart failure related admission in the last year OR
Has Class III heart failure in outpatient setting AND 2 of the following 4 conditions:
- Age ≥ 70
- BUN ≥ 43
- Cr ≥ 2.75
- SBP≤115 OR
- Is on inotropes (e.g., dobutamine, milrinone) OR intravenous diuretics OR intravenous heart failure treatments in emergency department OR in outpatient setting
Caregivers:
- Age > 18
- Fluent in English
- Consistent and reliable access to a phone
Exclusion Criteria for patients:
- Not having an ICD
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Communication training for cardiologists
The intervention consists of an educational workshop for heart failure physicians, a reminder system, and a system providing aggregated feedback on their conversations with patients about ICD deactivation.
|
Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness. Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study. Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills. |
|
Comparatore placebo: Control arm
Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
|
Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Prevalence of Conversations about ICD Deactivation
Lasso di tempo: after 1st clinical encounter after enrollment for intervention group
|
Whether deactivation discussion occurred difference between 1st and 3rd clinical encounters after enrollment
|
after 1st clinical encounter after enrollment for intervention group
|
|
Prevalence of Conversations about ICD Deactivation
Lasso di tempo: 3rd clinical encounter after enrollment for intervention group
|
Whether deactivation discussion occurred difference between 1st and 3rd clinical encounters after enrollment
|
3rd clinical encounter after enrollment for intervention group
|
|
Prevalence of Conversations about ICD Deactivation
Lasso di tempo: 3 months after enrollment for control group
|
Whether deactivation discussion occurred difference between 3 and 9 months after enrollment
|
3 months after enrollment for control group
|
|
Prevalence of Conversations about ICD Deactivation
Lasso di tempo: 9 months after enrollment for control group
|
Whether deactivation discussion occurred difference between 3 and 9 months after enrollment
|
9 months after enrollment for control group
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Prevalence of ICD Deactivation
Lasso di tempo: After 1st encounter after enrollment for intervention group
|
Whether ICD deactivation occurred difference between 1st and 3rd clinical encounters after enrollment
|
After 1st encounter after enrollment for intervention group
|
|
Prevalence of ICD Deactivation
Lasso di tempo: After 3rd encounter after enrollment for intervention group
|
Whether ICD deactivation occurred difference between 1st and 3rd clinical encounters after enrollment
|
After 3rd encounter after enrollment for intervention group
|
|
Prevalence of ICD Deactivation
Lasso di tempo: After 3 months after enrollment for control group
|
Whether ICD deactivation occurred difference between 3 and 9 months after enrollment
|
After 3 months after enrollment for control group
|
|
Prevalence of ICD Deactivation
Lasso di tempo: After 6 months after enrollment for control group
|
Whether ICD deactivation occurred difference between 3 and 9 months after enrollment
|
After 6 months after enrollment for control group
|
|
Psychological Outcomes in Bereaved Caregivers
Lasso di tempo: 4 weeks after patient death
|
4 weeks after patient death
|
|
|
Psychological Outcomes in Bereaved Caregivers
Lasso di tempo: 6 months after patient death
|
6 months after patient death
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Nathan E. Goldstein, MD, Icahn School Of Medicine At Mount Sinai
Pubblicazioni e link utili
Pubblicazioni generali
- Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002 Mar 21;346(12):877-83. doi: 10.1056/NEJMoa013474. Epub 2002 Mar 19.
- Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352(3):225-37. doi: 10.1056/NEJMoa043399. Erratum In: N Engl J Med. 2005 May 19;352(20):2146.
- Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996 Dec 26;335(26):1933-40. doi: 10.1056/NEJM199612263352601.
- Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999 Dec 16;341(25):1882-90. doi: 10.1056/NEJM199912163412503. Erratum In: N Engl J Med 2000 Apr 27;342(17):1300.
- Glikson M, Friedman PA. The implantable cardioverter defibrillator. Lancet. 2001 Apr 7;357(9262):1107-17. doi: 10.1016/S0140-6736(00)04263-X.
- Eckert M, Jones T. How does an implantable cardioverter defibrillator (ICD) affect the lives of patients and their families? Int J Nurs Pract. 2002 Jun;8(3):152-7. doi: 10.1046/j.1440-172x.2002.00357.x.
- Sears SF Jr, Conti JB. Quality of life and psychological functioning of icd patients. Heart. 2002 May;87(5):488-93. doi: 10.1136/heart.87.5.488. No abstract available.
- Gelfman LP, Sudore RL, Mather H, McKendrick K, Hutchinson MD, Lampert RJ, Lipman HI, Matlock DD, Swetz KM, Pinney SP, Morrison RS, Goldstein NE. Prognostic Awareness and Goals of Care Discussions Among Patients With Advanced Heart Failure. Circ Heart Fail. 2020 Sep;13(9):e006502. doi: 10.1161/CIRCHEARTFAILURE.119.006502. Epub 2020 Sep 2.
- Goldstein NE, Mather H, McKendrick K, Gelfman LP, Hutchinson MD, Lampert R, Lipman HI, Matlock DD, Strand JJ, Swetz KM, Kalman J, Kutner JS, Pinney S, Morrison RS. Improving Communication in Heart Failure Patient Care. J Am Coll Cardiol. 2019 Oct 1;74(13):1682-1692. doi: 10.1016/j.jacc.2019.07.058.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- GCO 09-0618
- 1R01HL102084-01A1 (Sovvenzione/contratto NIH degli Stati Uniti)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Arresto cardiaco
-
Region SkaneIscrizione su invitoInsufficienza cardiaca Classe II della New York Heart Association (NYHA). | Insufficienza cardiaca Classe III della New York Heart Association (NYHA).Svezia
-
Yonsei UniversityReclutamentoIschemic Heart Disease | Cardiopatia Non IschemicaCorea del Sud
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... e altri collaboratoriTerminatoInsufficienza cardiaca, sistolica | Insufficienza cardiaca con frazione di eiezione ridotta | Scompenso cardiaco Classe IV della New York Heart Association | Scompenso cardiaco Classe III della New York Heart AssociationPolonia
-
University of WashingtonAmerican Heart AssociationCompletatoInsufficienza cardiaca, congestizia | Alterazione mitocondriale | Scompenso cardiaco Classe IV della New York Heart AssociationStati Uniti
-
Portuguese Association of Interventional CardiologyMedtronicReclutamentoStenosi Aortica Sintomatica Grave (Definita come Classe New York Heart Association (NYHA) ≥ II)Portogallo
Prove cliniche su Communication training for cardiologists.
-
Jacobs University Bremen gGmbHGoethe University; University Hospital Ulm; Techniker Krankenkasse; German Coalition... e altri collaboratoriCompletatoCorrelati alla gravidanzaGermania
-
Children's Hospital of PhiladelphiaCompletato
-
Hebrew University of JerusalemSconosciutoDisturbo dello spettro autisticoIsraele
-
Universitätsklinikum Hamburg-EppendorfNon ancora reclutamento
-
University of ArkansasNational Institute on Minority Health and Health Disparities (NIMHD); Virginia... e altri collaboratoriNon ancora reclutamentoAtteggiamenti | Conoscenza | Intenzione comportamentaleStati Uniti
-
Cairo UniversityCompletatoSclerosi multipla recidivante-remittenteEgitto